What we know of their benefits, limitations, and toxicities. Mechanisms & therapeutic role (in metastatic bladder cancer) Enfortumab vedotin (EV) EV is an antibody-drug conjugate (ADC) targeting nectin-4 (a cell-surface adhesion molecule expressed in urothelial carcinoma). The antibody binds nectin-4, is internalized, and releases a cytotoxic payload (monomethyl auristatin E, MMAE) inside the cancer cell,ContinueContinue reading “Comparison of enfortumab vedotin (EV, aka Padcev) and pembrolizumab (Keytruda) in metastatic urothelial/bladder cancer”
Random Postings, Thoughts about Medicine and Life
Dr Bob, Brain Mechanic 